MANE (MANE) had its price target raised by Leerink Partners from $75.00 to $90.00. They now have an "outperform" rating on the stock.
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates [Yahoo! Finance]
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
MANE (MANE) was upgraded by Zacks Research to "hold".